ISSN: 2279 - 0594

Available Online at www.jbpr.in

Journal of Biomedical and Pharmaceutical Research 2 (4) 2013, 15-19

REVIEW ARTICLE

HEMATOPOIETIC GROWTH ASPECTS: MANIFESTATION OF VULNERABILITIES AND PROSPERITY IN HUMAN CANCER

***Pramod Khatri[1], Madhulika Kabra[2]**

[1]Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

[2]Professor of Pediatrics, Genetics Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India

Received 10 May 2013; Revised 28 May 2013; Accepted 20 June 2013

ABSTRACT

A regular reaction of cancer medicine is bone marrow concealment. The resulting myelosuppression and iron deficiency can cause huge morbidity and mortality for patients. Mediators, for example granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be supportive to enhance this sorrow of blood counts; however these executors have dangers which likewise need to be deliberately weighed .

KEYWORDS: Granulocyte colony stimulating factors (GCSF), Pegfilgastrim, and Erythropoietin stimulating agents (ESAs)

INTRODUCTION:

Around the most widely recognized reactions for numerous cytotoxic antineoplastic is bone marrow concealment which causes neutropenia, iron deficiency, and thrombocytopenia. Improved comprehension of the pathways for improvement of platelets has prompted the improvement of particular cancer factors, particularly to support red and white platelet creation. Recently, there have been particular proposals for cancer factor utilization, especially in light of antagonistic results connected with erythropoietin analogs. As choice of cancer medicine overall is customized to the individual, the medication and aversion of reactions identified with bone marrow concealment is customized besides, with a watchful appraisal of dangers and benefit of cancer factor medication to guide utilizat.

GRANULOCYTE COLONY CANCER FACTORS (GCSF):

The utilization of myeloid cancer aspect has huge affected oncology care, not just by decreasing irresistible difficulties identified with febrile neutropenia, however by keeping up chemotherapy dose intensity and dose density, also (Pettengell et al., 1992). Febrile neutropenia (FN) is outlined as an Absolute neutrophil count (ANC) of <0.5 10^9/L, or an ANC that is relied upon to decrease to <500 cells/ml with the following 48 h with fever or clinical indications of sepsis (Aapro et al., 2011). FN is a major confusion of chemotherapy medicine and might prompt medication delays or chemotherapy dosage decreases, patients which might sway general survival as depicted previously. Khan et al. (2008) discovered that dose deferral was the most widely recognized neutropenic event and happened in 30% of patients. Furthermore, dose decline because of neutropenia was noted in 20% of patients. Essential prophylaxis implies the counteractive action of neutropenic confusions by utilization of GCSFS throughout the first cycle of chemotherapy. The utilization of prophylactic cancer components requires an evaluation of every patient's inalienable danger of advancing FN. As per the 2006 ASCO Guidelines and the 2010 Guidelines from the Infectious Diseases Society of America, essential GCSF prophylaxis is proposed if the danger of FN is more stupendous than 20% (Smith et al., 2006;). A patients' hazard for FN hinges on age, comorbid therapeutic conditions, malady characteristics, and myelotoxicity of the particular chemotherapy regimen to be controlled (see Figure 1). Additionally, for regimens with abbreviated span between cycles, "measurement thick regimens," the utilization of GCSFS is needed. Patients with certain danger elements (fig 1.) are at expanded danger of FN in spite of the fact that the particular regimen being utilized might not have a high hazard in patients without such hazard elements. For those patients the utilization of prophylactic medicine is prescribed simultaneously. Trials have showed that it is more savvy to utilize essential prophylaxis as a part of these patients as the hospitalization of neutropenic patients is costly (Vogel et al., 2005;). In a meta-analysis that incorporated 3493 patients from 17 randomized controlled trials, there was a 46% decline in danger of febrile neutropenia (RR of 0.54, 95% CI 0.43e0.67), a 45% abatement in contamination identified mortality (RR of

*Corresponding author: Pramod Khatri | Email: pramodsinghkhatri@gmail.com

0.55, 95% Cl 0.33e0.90), and a 40% decline taking all things together reason mortality (RR 0.6, 95% Cl 0.43e0.87) throughout the time of chemotherapy with the utilization of GCSF prophylaxis (Kuderer et al., 2007).

The suggested dosage for filgrastim or GCSF is 5 mg/kg for every day and for sargramostim (GM-CSF) is 250 mg/m2 for every day. Ordinarily, treatment starts 1e3 days after chemotherapy and happens daily until neutrophil recuperation has been realized (Ozer et al., 2000). Pegfilgastrim is the pegylated manifestation of GCSF and has a more extended half-life, hence taking into consideration a solitary dose. The normal dose of Pegfilgastrim is 6 mg given one day after chemotherapy. It has been showed that Pegfilgrastim is as viable as filgrastim, and is more favorable for patients (Holmes et al., 2002).

It is significant to note that the utilization of myeloid cancer factors as either primary or secondary counteractive action of neutropenia is not without reactions or risk. A standout amongst the most generally reported reactions is bone pain. A review study examined the rates of bone agony on Pegfilgrastim, filgrastim, and without either agent (Gregory et al., 2010). The rate of any evaluation bone pain with Pegfilgrastim was 62.3% for Pegfilgrastim and 66.1% for filgrastim, with rate of evaluation 3/4 bone pain being 6.6% with Pegfilgrastim and 7.9% with filgrastim. The underlying threat seemed to impact the rate of extreme bone pain (Non-small cell lung cancer (19.6%) vs. breast cancer (6.2%)). The contribution of regimen given (taxane or not), age, and sexual orientation was blended relying upon intensity of bone pain. Of note, while studies with Pegfilgrastim as contrasted with no cancer factor utilize, the rate of any grade bone pain was higher with Pegfilgrastim (32.7% vs. 23%), be that as it may, the rates of extreme pain were comparative (3.4% vs. 2.0%).

Uncommon, yet remarkable toxicities with myeloid cancer factor incorporate expanded bleomycin-related pulmonary lethality, splenic burst, and intense leukemia. Bleomycin pulmonary toxicity was seen in 26% of bleomycin-treated with Hodgkin's lymphoma who received GCSF and in 9% of patients who did not gain GCSF (Martin et al., 2005). However the improvement of pulmonary lethality with GCSF has not been seen in other bleomycin treated malignancies, for example non-Hodgkin's lymphoma and testicular cancer malignancy (Bastion et al., 1994). Right now, this connotation is not a contraindication for medication, on the other hand it is imperative for clinicians to be aware and advise their patients. Splenic crack has been accounted for in generally healthy bone marrow transplant donors and additionally recipients of hematopoietic stem cell transplants, and seems, by all accounts, to be rarer in patients receiving prophylactic GCSF in the setting of chemotherapy for solid tumors. The later risk of developing medication related myeloid dyscrasia or leukemia has been examined in patients treated with GCSF. A review in over 12,000 patients treated with these agents did uncover infrequent cancer of later AML /MDS which was higher in those who gained GCSF (RR 1.92, P ¼ 0.007); however all-cause mortality was lower in those who received GCSF. At this time, cancer factors are not contraindicated in any particular population.

ERYTHROPOIETIN ANALOGS:

In cancer patients, pallor can have various and covering etiologies incorporating toxicity of chemotherapy, direct bone marrow inclusion, chronic blood loss with draining from tumors, (for example in gastrointestinal cancers), and anemia of chronic disease/inflammation. Erythropoietin (EPO) is secreted fundamentally by the kidney and is needed for the formation of red platelets. Erythropoietin Stimulating Agents (ESAs) are usually utilized in patients with hemoglobin of less than 10 and incorporate agents, for example epoetin and darbepoetin. ESAs have been indicated in clinical trials to reduce the transfusion requirement and increment the hemoglobin in patients with chemotherapy incited anemia (Rizzo et al., 2010). However, these trials have not indicated that ESAs drag out survival, or enhance personal satisfaction in these patients (Pronzato et al.,2010). A meta-analysis performed by Bohlius et al. (2006) compared 57 studies incorporating 9353 patients allotted to ESAs and blood transfusions vs. just blood transfusions discovered that in patients with a hemoglobin of less than 12, ESAs altogether expanded the probability of acquiring an expansion in HGB of no less than 2 g/dl from baseline (RR of a HGB reaction 3.4, 95% Cl 3.1e3.8). ESAs were likewise discovered to diminish the utilization of RBC transfusion (relative risk [RR] 0.64, 95% Cl 0.60e0.68) and patients treated with an ESA gained on normal one unit less of red platelets than those in the control group (Bohlius et al.,2006). ESAs are an alternative for patients who are loath to blood transfusions for individual or religious explanations. Transfusions are not without different risk incorporating transfusion responses, iron overload, viral contaminations, and the danger of alloantibody cancer.

ESAs, though, have been connected with various detrimental results in tumor patients incorporating an expanded danger of stroke and venous thromboembolism, more regrettable tumor results and general expanded mortality. The meta analysis depicted above by Bohlius and partners reported a close multiplying in the rate of thromboembolic occasions, from 3.8% for patients not on

ESA and 6.1% when ESAs were given. Essentially, an additional metaanalysis performed by Bennett et al. (2008) additionally indicated that VTE risk was expanded in patients getting ESAs (7.5 vs. 4.9% in patients not accepting ESAs, relative risk 1.57 [95% Cl 1.31e1.87]). Patients who were cured with ESAs had more amazing all-cause mortality (HR ¼ 1.10, 95% Cl 1.01e1.2) in spite of the fact that this was not statically significant (P ¼ 0.11). A later meta-analysis likewise discovered disservice to mortality in a differing group of cancer patients treated with ESAs to the general population assessed (HR 1.06, 95% Cl 1.00e1.12) (Bohlius et al., 2009).

One of the main apprehensions with the utilization of ESAs started by the perception of worse mortality is that tumor cells of different histologies have erythropoietin receptors and might, actually, be empowered by the ESAs (Acs et al., 2001, 2004) With the detections of worse results in patients treated with ESAs, both the Us Food and Drug Administration (FDA) and the European Medicines Agency issued warnings against the utilization of ESAs especially when treating patients with an objective of cure. The 2010 ASH/ASCO (American Society of Hematology/American Society of Clinical Oncology) Guidelines suggest a careful workup for different details for anemia before launch of ESAs and additionally talk of the potential profits and damages of ESAs. They likewise focused on that ESAs might as well just be utilized within iron deficiency connected with chemotherapy when the hemoglobin is <10 g/dl and the patient is symptomatic and not in patients who are not presently receiving chemotherapy. Patients at an expanded risk for thromboembolic events, for example those with a history of thrombosis, surgery, prolonged periods of immobilization or constrained movement, might as well acknowledge the risks and benefits prudently before the beginning of ESA treatment (Rizzo et al., 2010)

In light of the previously stated concerns with intensified outcome connected with ESA therapy, the United States Food and Drug Administration (FDA) has commanded a risk evaluation and mitigation strategy (REMS) for hospital and medical practitioners that recommend ESA treatment. The producer of presently accessible ESA's was obliged to develop a program for prescribers, ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe utilization of ESAs) with particular training on the antagonistic results connected with these agents. There is likewise instructive informative data for patients (US FDA, 2010). These materials blueprint in particular that the dangers of ESAs incorporate expanded tumor progression and expiration from cancer malignancy, and also expanded risk of myocardial infarction, heart failure, stroke, and blood clumps. healthcare experts must be re-selected in the project every three years.

CONCLUSIONS:

Reaction profiles are regularly a major encounter in cancer malignancy treatment. Inimical hematopoietic reaction to medication might at last dissuade a patient from receiving the suitable medication. Age, other comorbid conditions, development of infection and toxicity of chemotherapy are frequently factors that impact how a patient will respond to a pill. Granulocyte colony cancer factors (GCSF) could be lifesaving when the patients' inclusive risk for febrile neutropenia is recognized to be greater than 20%. Furthermore, chemotherapy associated anemia that need blood transfusions may be connected with undesirable risks that may be reduced by utilizing ESAs. Nonetheless, the distinctive risks of utilizing such treatments must be weighed against the profits. An individualized methodology must be utilized to verify the probability of symptoms for patients. The point when determined safe to utilize, cancer factors might prolong the duration a patient may have the capacity to undergo chemotherapy ,and might at last accelerate cancer outcomes

Figure 1: Febrile Neutropenia risk features.



DISCLOSURE:

The author reports no conflicts of interest in this work.

REFERENCES:

1. Aapro, M.S., Bohlius, J., Cameron, D.A., Dal Lago, L., Donnelly, J.P., et al., 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. European Journal of Cancer 47, 8e32.
2. Acs, G., Acs, P., Beckwoth, S.M., et al., 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Research 61, 3561e3565.
3. Acs, G., Chen, M., Xu, X., et al., 2004. Autocrine erythropoietin signaling inhibits hypoxia induced apoptosis in human breast carcinoma cells. Cancer Letters 214, 243e251.
4. Bastion, Y., Reyes, F., Bosly, A., et al., 1994. Possible toxicity with the association of G-CSF and bleomycin. Lancet 343, 1221e1222.
5. Bennett, C.L., Silver, S.M., Djulbegovic, B., Samaras, A.T., Blau, C.A., et al., 2008. Venous thromboembolism and mortality associated

with recombinant erythropoietin and darbepoetin administration for the treatment of cancer- associated anemia. Journal of the American Medical Association 299, 914e924.

6. Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., et al., Jul 19, 2006. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Systemic Review 3.
7. Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., et al., 2009. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373, 1532e1542.
8. Gregory, S.A., Schwartzberg, L.S., Mo, M., et al., 2010. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Community Oncology 7, 297e308.
9. Holmes, F.A., Jones, S.E., O'Shaughnessy, J., Vukelja, S., George, T.,2002. Comparable efficacy and safety profiles of once-per- cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose- finding study in women with breast cancer. Annals of Oncology 13, 903e909.
10. Khan, S., Dhadda, A., Fyfe, D., et al., 2008. Impact of neutropenia on delivering planned chemotherapy for solid tumors. European Journal of Cancer Care 17, 19e25.
11. Kuderer, N.M., Dale, D.C., Carwford, J., et al., 2007. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. Journal of Clinical Oncology 25, 3158e3167.
12. Lyman, G.H., Dale, D.C., Wolff, D.A., et al., 2010. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. Journal of Clinical Oncology 28, 2914e2924.
13. Martin, W.G., Ristow, K.M., Habermann, T.M., et al., 2005.Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. Journal of Clinical Oncology 23, 7614e7620.
14. Ozer, H., Armitage, J.O., Bennett, C.L., et al., 2000. 2000 update of recommendations for the use of hematopoietic colony- stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 18, 3558e3585.
15. Pettengell, R., Gurney, H., Radford, J.A., et al., 1992. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80, 1430e1436.
16. Pronzato, P., Cortesi, E., van der Rijt, C.C., Bols, A., Moreno- Nogueira, J.A., et al., 2010. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist 15, 935e943.
17. Rizzo, J.D., Brouwers, M., Hurley, P., Seidenfeld, J., Arcasoy, M.O.,2010. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116, 4045e4059.
18. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., et al., 2006. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 24, 3187e3205.

